Treatment of Relapsed Acute Leukemia After Allogeneic Stem Cell Transplantation: Disease Stabilization Through Chemotherapy, Immunomodulatory Treatment and Immunotherapy
Phase 1/Phase 2
18 Years
90 Years
18 Years
90 Years
Not Enrolling
Both
Acute Myeloid Leukemia
Both
Acute Myeloid Leukemia
Trial Information
Treatment of Relapsed Acute Leukemia After Allogeneic Stem Cell Transplantation: Disease Stabilization Through Chemotherapy, Immunomodulatory Treatment and Immunotherapy
Inclusion Criteria:
- AML relapse within one year after transplantation
- Blood and marrow sampling being possible
- Expected survival at least 4 weeks
- No expected drug interactions
- Informed consent possible
Exclusion Criteria:
- Intolerance to any study drug
- Serious kidney or liver disease
- Informed consent not possible
- Previous pancreatitis
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Disease stabilization
Outcome Description:
Strict criteria defined in the protocol.
Outcome Time Frame:
5 years
Safety Issue:
Yes
Authority:
Norway: Innovest, Haukeland University Hospital, N-5021 Bergen, Norway
Study ID:
Allo-Relapse-2011
NCT ID:
NCT01369368
Start Date:
October 2011
Completion Date:
October 2020
Related Keywords:
- Acute Myeloid Leukemia
- Acute myeloid leukemia
- Allogeneic stem cell transplantation
- Relapse
- Disease stabilization, survival
- Leukemia
- Leukemia, Myeloid, Acute
- Leukemia, Myeloid
Name | Location |
|---|
